Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J M MichotO Lambotte

Abstract

Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting tumour responses. By unbalancing the immune system, these new immunotherapies also generate dysimmune toxicities, called immune-related adverse events (IRAEs) that mainly involve the gut, skin, endocrine glands, liver, and lung but can potentially affect any tissue. In view of their undisputed clinical efficacy, anti-CTLA-4 and anti-PD-1 antibodies are entering in the routine oncological practice, and the number of patients exposed to these drugs will increase dramatically in the near future. Although steroids can be used to treat these IRAEs, the associated immunosuppression may compromise the antitumour response. Oncologists must be ready to detect and manage these new types of adverse events. This review focuses on the mechanisms of IRA...Continue Reading

Associated Clinical Trials

References

Oct 12, 1995·The New England Journal of Medicine·P J JohnsonR Williams
Jul 19, 2005·Human Genetics·Alexandra ZhernakovaBobby P C Koeleman
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasJesus Gomez-Navarro
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly E BeckJames C Yang
Jun 27, 2006·Journal of Immunotherapy·Ajay V MakerSteven A Rosenberg
Oct 4, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·A EckertL Thomas
Dec 5, 2008·Cancer Immunology, Immunotherapy : CII·Ilyssa O GordonThomas F Gajewski
Feb 27, 2009·Journal of Immunotherapy·Mojtaba AkhtariMartha L Arellano
Apr 7, 2009·Human Immunology·Mercedes Fernández-MestreZulay Layrisse
Jul 10, 2009·The New England Journal of Medicine·Fouad FadelBertrand Knebelmann
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Nov 4, 2011·The New England Journal of Medicine·Julie DelyonThierry Lambert
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michela MaurPierfranco Conte
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grégoire BerthodOlivier Michielin
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberAxel Hauschild
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 27, 2012·Gut·Peter A BanksUNKNOWN Acute Pancreatitis Classification Working Group
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasAxel Hauschild
Feb 15, 2013·Investigational New Drugs·Kyung Won KimNageatte Ibrahim
Mar 6, 2013·Chest·Igor Z BarjaktarevicDiane Stover
Mar 15, 2013·Practical Neurology·Ilja BotDieta Brandsma
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Oct 2, 2013·Oncoimmunology·Christel DevaudMichael H Kershaw
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Apr 2, 2014·Investigational New Drugs·Hassane IzzedinePhilippe Rouvier
Apr 4, 2014·Science Translational Medicine·Shintaro IwamaPatrizio Caturegli
May 30, 2014·Science Translational Medicine·Edward ChaLawrence Fong
Jun 10, 2014·Journal of Immunotherapy·Pauline du RusquecBrigitte Dréno

❮ Previous
Next ❯

Citations

Apr 14, 2016·Ocular Immunology and Inflammation·Emmett T CunninghamManfred Zierhut
Apr 29, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MansonR Houot
May 26, 2016·Expert Opinion on Biological Therapy·Myrna R Nahas, David Avigan
Jul 28, 2016·Gastroenterology Research and Practice·Guohui Jiao, Bangmao Wang
Oct 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Francesco FacchinettiMarcello Tiseo
Jul 18, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kohei FujitaTadashi Mio
Aug 20, 2016·Nature Reviews. Rheumatology·Michiel van der VlistLinde Meyaard
Oct 26, 2016·Journal for Immunotherapy of Cancer·Bridgette A KanzDouglas B Johnson
Oct 8, 2016·Cancer Immunology, Immunotherapy : CII·Peter EllmarkThomas H Tötterman
Nov 1, 2016·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Terufumi KuboToshihiko Torigoe
Nov 5, 2016·International Journal of Cancer. Journal International Du Cancer·Yan TieHeng Zheng
Dec 21, 2016·Cell Research·Atsushi Tanaka, Shimon Sakaguchi
Jan 7, 2017·Nature Reviews. Drug Discovery·W Joost LesterhuisRichard A Lake
Jan 14, 2017·Arthritis & Rheumatology·Maria E Suarez-AlmazorAdi Diab
Mar 23, 2017·Pharmacology & Therapeutics·Jason Lohmueller, Olivera J Finn
Mar 30, 2017·Expert Opinion on Drug Safety·Carlo GenovaFrancesco Grossi
Mar 28, 2017·British Journal of Clinical Pharmacology·Sarah L GaronElizabeth J Phillips
May 4, 2017·Expert Review of Respiratory Medicine·Chiara LazzariMariacarmela Santarpia
Apr 12, 2017·Antioxidants & Redox Signaling·Carlo Gabriele TocchettiGiuseppe Mercuro
Apr 20, 2017·Der Pathologe·V H KoelzerK D Mertz
Apr 14, 2017·Current Opinion in Pulmonary Medicine·Vickie R Shannon
Apr 22, 2017·The Journal of Infectious Diseases·Cynthia L GayUNKNOWN AIDS Clinical Trials 5326 Study Team
Jan 19, 2017·Melanoma Research·Arjun GuptaThomas Froehlich
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Mar 16, 2017·The American Journal of Surgical Pathology·Jonathan H ChenRicard Masia
Mar 8, 2017·Journal of Immunotherapy·Marjorie BernierMarion Sassier
Jun 29, 2017·AJR. American Journal of Roentgenology·Gary X WangFlorian J Fintelmann
Jun 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ryan Ying Cong TanAngela Takano
Jun 19, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alice Bernard-TessierJean-Marie Michot
Nov 17, 2017·Virchows Archiv : an International Journal of Pathology·Naziheh AssarzadeganRobert A Anders
Feb 17, 2018·Nature Reviews. Cancer·Wilfred NgwaSilvia C Formenti
Nov 15, 2017·International Journal of Molecular Sciences·Naeem K PatilEdward R Sherwood
Jan 1, 2018·Cancer Immunology, Immunotherapy : CII·Helen M McGuirePeter Hersey
Mar 13, 2018·Expert Opinion on Therapeutic Targets·Karolina Nemes, Michael C Frühwald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

American Society of Clinical Oncology Educational Book
Michael A Postow
Annals of Translational Medicine
Cristina TeixidóRafael Rosell
Nature Reviews. Drug Discovery
Kathleen M MahoneyGordon J Freeman
© 2022 Meta ULC. All rights reserved